Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models

References

• Kaplon H, Reichert JM. Antibodies to watch in 2019. MAbs. 2019;11(2):219–13. doi:https://doi.org/10.1080/19420862.2018.1556465.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18:585–608.
   PubMed Web of Science ®Google Scholar
• Kareva I, Zutshi A, Kabilan S. Guiding principles for mechanistic modeling of bispecific antibodies. Prog Biophys Mol Biol. 2018;139:59–72. doi:https://doi.org/10.1016/j.pbiomolbio.2018.08.011.
   PubMed Web of Science ®Google Scholar
• Chen Y, Xu Y. Pharmacokinetics of bispecific antibody. Curr Pharmacol Rep. 2017;3:126–37. doi:https://doi.org/10.1007/s40495-017-0090-5.
   Google Scholar
• Datta-Mannan A, Brown RM, Fitchett J, Heng AR, Balasubramaniam D, Pereira J, Croy JE. Modulation of the biophysical properties of bifunctional antibodies as a strategy for mitigating poor pharmacokinetics. Biochemistry. 2019;58(28):3116–32. doi:https://doi.org/10.1021/acs.biochem.9b00074.
   PubMed Web of Science ®Google Scholar
• Ma M, Colletti K, Yang TY, Leung S, Pederson S, Hottenstein CS, Xu X, Warrino D, Wakshull E. Bioanalytical challenges and unique considerations to support pharmacokinetic characterization of bispecific biotherapeutics. Bioanalysis. 2019;11(5):427–35. doi:https://doi.org/10.4155/bio-2018-0146.
   PubMed Web of Science ®Google Scholar
• Shah DK. Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics. J Pharmacokinet Pharmacodyn. 2015;42(5):553–71. doi:https://doi.org/10.1007/s10928-015-9447-8.
   PubMed Web of Science ®Google Scholar
• Avery LB, Wade J, Wang M, Tam A, King A, Piche-Nicholas N, Kavosi MS, Penn S, Cirelli D, Kurz JC, et al. Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics. MAbs. 2018;10(2):244–55. doi:https://doi.org/10.1080/19420862.2017.1417718.
   PubMed Web of Science ®Google Scholar
• Liu L. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell. 2018;9(1):15–32. doi:https://doi.org/10.1007/s13238-017-0408-4.
   PubMed Web of Science ®Google Scholar
• Borrok MJ, Wu Y, Beyaz N, Yu XQ, Oganesyan V, Dall’Acqua WF, Tsui P. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling. J Biol Chem. 2015;290(7):4282–90. doi:https://doi.org/10.1074/jbc.M114.603712.
   PubMed Web of Science ®Google Scholar
• Dall’Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem. 2006;281(33):23514–24. doi:https://doi.org/10.1074/jbc.M604292200.
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715–25. doi:https://doi.org/10.1038/nri2155.
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Witcher DR, Lu J, Wroblewski VJ. Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys. MAbs. 2012;4(2):267–73. doi:https://doi.org/10.4161/mabs.4.2.19364.
   PubMed Web of Science ®Google Scholar
• Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6(9):576–88. doi:https://doi.org/10.1002/psp4.12224.
   PubMedGoogle Scholar
• Ward ES, Zhou J, Ghetie V, Ober RJ. Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int Immunol. 2003;15(2):187–95. doi:https://doi.org/10.1093/intimm/dxg018.
   PubMed Web of Science ®Google Scholar
• Robbie GJ, Criste R, Dall’acqua WF, Jensen K, Patel NK, Losonsky GA, Griffin MP. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother. 2013;57(12):6147–53. doi:https://doi.org/10.1128/AAC.01285-13.
   PubMed Web of Science ®Google Scholar
• Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IWL, Sproule TJ, Lazar GA, Roopenian DC, Desjarlais JR. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol. 2010;28(2):157–59. doi:https://doi.org/10.1038/nbt.1601.
   PubMed Web of Science ®Google Scholar
• Mackness BC, Jaworski JA, Boudanova E, Park A, Valente D, Mauriac C, Pasquier O, Schmidt T, Kabiri M, Kandira A, et al. Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life. MAbs. 2019;11(7):1276–88. doi:https://doi.org/10.1080/19420862.2019.1633883.
   PubMed Web of Science ®Google Scholar
• Wang X, Mathieu M, Brezski RJ. IgG Fc engineering to modulate antibody effector functions. Protein Cell. 2018;9(1):63–73. doi:https://doi.org/10.1007/s13238-017-0473-8.
   PubMed Web of Science ®Google Scholar
• Lee CH, Kang TH, Godon O, Watanabe M, Delidakis G, Gillis CM, Sterlin D, Hardy D, Cogné M, Macdonald LE, et al. An engineered human Fc domain that behaves like a pH-toggle switch for ultra-long circulation persistence. Nat Commun. 2019;10(1):5031. doi:https://doi.org/10.1038/s41467-019-13108-2.
   PubMed Web of Science ®Google Scholar
• Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the ‘high-hanging fruit’. Nat Rev Drug Discov. 2018;17:197–223.
   PubMed Web of Science ®Google Scholar
• Han C, Gunn GR, Marini JC, Shankar G, Han Hsu H, Davis HM. Pharmacokinetics and immunogenicity investigation of a human anti-interleukin-17 monoclonal antibody in non-naïve cynomolgus monkeys. Drug Metab Dispos. 2015;43(5):762–70. doi:https://doi.org/10.1124/dmd.114.062679.
   PubMed Web of Science ®Google Scholar
• Vaccaro C, Bawdon R, Wanjie S, Ober RJ, Ward ES. Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies. Proc Natl Acad Sci U S A. 2006;103(49):18709–14. doi:https://doi.org/10.1073/pnas.0606304103.
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Jiang W, Wroblewski VJ. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab Dispos. 2007;35(1):86–94. doi:https://doi.org/10.1124/dmd.106.011734.
   PubMed Web of Science ®Google Scholar
• Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol. 2001;13(12):1551–59. doi:https://doi.org/10.1093/intimm/13.12.1551.
   PubMed Web of Science ®Google Scholar
• Dall’Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol. 2002;169(9):5171–80. doi:https://doi.org/10.4049/jimmunol.169.9.5171.
   PubMed Web of Science ®Google Scholar
• Proetzel G, Roopenian DC. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies. Methods. 2014;65(1):148–53. doi:https://doi.org/10.1016/j.ymeth.2013.07.005.
   PubMed Web of Science ®Google Scholar
• Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, Presta LG, Meng YG, Roopenian DC. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol. 2006;18(12):1759–69. doi:https://doi.org/10.1093/intimm/dxl110.
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilesh S, Jung N, Petkova S, Avanessian L, Choi EY, Shaffer DJ, et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol. 2003;170(7):3528–33. doi:https://doi.org/10.4049/jimmunol.170.7.3528.
   PubMed Web of Science ®Google Scholar
• Avery LB, Wang M, Kavosi MS, Joyce A, Kurz JC, Fan YY, Dowty ME, Zhang M, Zhang Y, Cheng A, et al. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. MAbs. 2016;8(6):1064–78. doi:https://doi.org/10.1080/19420862.2016.1193660.
   PubMed Web of Science ®Google Scholar
• Betts A, Keunecke A, van Steeg TJ, van der Graaf PH, Avery LB, Jones H, Berkhout J. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach. MAbs. 2018;10(5):751–64. doi:https://doi.org/10.1080/19420862.2018.1462429.
   PubMed Web of Science ®Google Scholar
• Tam SH, McCarthy SG, Brosnan K, Goldberg KM, Scallon BJ. Correlations between pharmacokinetics of IgG antibodies in primates vs FcRn-transgenic mice reveal a rodent model with predictive capabilities. MAbs. 2013;5:397–405.
   PubMed Web of Science ®Google Scholar
• Steinmetz A, Vallée F, Beil C, Lange C, Baurin N, Beninga J, Capdevila C, Corvey C, Dupuy A, Ferrari P, et al. CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications. MAbs. 2016;8(5):867–78. doi:https://doi.org/10.1080/19420862.2016.1162932.
   PubMed Web of Science ®Google Scholar
• van Meer PJK, Kooijman M, Brinks V, Gispen-de Wied CC, Silva-Lima B, Moors EHM, Schellekens H. Immunogenicity of mAbs in non-human primates during nonclinical safety assessment. MAbs. 2013;5(5):810–16. doi:https://doi.org/10.4161/mabs.25234.
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Chow CK, Dickinson C, Driver D, Lu J, Witcher DR, Wroblewski VJ. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys. Drug Metab Dispos. 2012;40(8):1545–55. doi:https://doi.org/10.1124/dmd.112.045864.
   PubMed Web of Science ®Google Scholar
• Hötzel I, Theil FP, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, et al. A strategy for risk mitigation of antibodies with fast clearance. MAbs. 2012;4(6):753–60. doi:https://doi.org/10.4161/mabs.22189.
   PubMed Web of Science ®Google Scholar
• Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem. 2010;21(12):2153–63. doi:https://doi.org/10.1021/bc100261d.
   PubMed Web of Science ®Google Scholar
• Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, Aso Y, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel. 2010;23(5):385–92. doi:https://doi.org/10.1093/protein/gzq009.
   PubMed Web of Science ®Google Scholar
• Haraya K, Tachibana T, Nanami M, Ishigai M. Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody. Xenobiotica. 2014;44(12):1127–34. doi:https://doi.org/10.3109/00498254.2014.941963.
   PubMed Web of Science ®Google Scholar
• Mahmood I. Interspecies scaling of protein drugs: prediction of clearance from animals to humans. J Pharm Sci. 2004;93(1):177–85. doi:https://doi.org/10.1002/jps.10531.
   PubMed Web of Science ®Google Scholar
• Wang W, Prueksaritanont T. Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited. Biopharm Drug Dispos. 2010;31:253–63.
   PubMed Web of Science ®Google Scholar
• Kazazi-Hyseni F, Beijnen JH, Schellens JHM. Bevacizumab. Oncologist. 2010;15(8):819–25. doi:https://doi.org/10.1634/theoncologist.2009-0317.
   PubMed Web of Science ®Google Scholar
• Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol. 2008;62(5):779–86. doi:https://doi.org/10.1007/s00280-007-0664-8.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Avastin® (bevacizumab). Highlights of prescribing information. 2018 [accessed 2020 Aug 27]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125085s323lbl.pdf.
   Google Scholar
• Ternant D, Ducourau E, Fuzibet P, Vignault C, Watier H, Lequerré T, Le Loët X, Vittecoq O, Goupille P, Mulleman D, et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015;79(2):286–97. doi:https://doi.org/10.1111/bcp.12509.
   PubMed Web of Science ®Google Scholar
• Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid ar thritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25(6):1700–21. doi:https://doi.org/10.1016/S0149-2918(03)80164-9.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Humira® (adalimumab). Highlights of prescribing information. 2020 [accessed 2020 Aug 27]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125057s415lbl.pdf.
   Google Scholar